Menu

ISTOCK, HENRIK5000

Ebola Update: More Experimental Treatments, Health Workers at Risk

The number of cases in Democratic Republic of Congo’s latest outbreak of the virus has now surpassed 100.  

Aug 23, 2018
Catherine Offord

Health workers in Democratic Republic of Congo have begun giving patients two experimental treatments to tackle the latest outbreak of Ebola as the number of cases climbs above 100, Reuters reports. The first dose of Gilead Science’s antiviral drug Remdesivir was administered on Tuesday (August 21), while the monoclonal antibody treatment mAb114 was deployed nearly two weeks ago. 

“As of 20 August 2018, a total of 102 confirmed and probable [Ebola virus disease] cases, including 59 deaths, have been reported,” the World Health Organization (WHO) writes in a situation report published yesterday (August 22). Besides mAb114, “The Ethics Committee in the Democratic Republic of the Congo has approved the use of four additional experimental therapeutics, namely: ZMapp, Remdesivir, Favipiravir, and Regn3450 - 3471 – 3479” to be used by Ebola treatment centers.

See “Q&A: Anthony Fauci Describes an Experimental Ebola Treatment

The latest outbreak was discovered at the beginning of August near Beni, a city in the eastern part of the country that is currently experiencing militia violence—an obstacle to the work of health authorities trying to contain the virus. “We don’t know if we are having all transmission chains identified,” WHO spokesman Tarik Jasarevic said during a news briefing in Geneva, Reuters reported last week (August 17). “The worst-case scenario is that we have these security blindspots where the epidemic could take hold that we don’t know about.”

See “New Ebola Outbreak in Democratic Republic of Congo

Health workers have been particularly affected by the latest outbreak, accounting for 12 of the 75 cases that have been confirmed so far. “There’s an extremely low level of knowledge and awareness about Ebola in the area,” epidemiologist Peter Salama, head of the WHO’s response to the outbreak, tells Science. “Early on, the health care workers took no precautions whatsoever, and unfortunately, we’re expecting more confirmed cases from that group.”

Meanwhile, vaccination teams are continuing to administer an experimental Ebola vaccine, Merck’s rVSV-ZEBOV, to health workers and people in contact with Ebola patients. Reuters reports that 2,179 people have received the vaccine so far, and more doses are on their way to Beni now.

See “Experimental Ebola Vaccinations to Resume in Democratic Republic of Congo

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.